The European Haemophilia Consortium / X
Jul 1, 2025, 18:13
5th EHC HTA Stakeholder Meeting: Driving Change for the Bleeding Disorders Community
The European Haemophilia Consortium recently shared a post on X:
”We had a meaningful day advocating for patients with bleeding disorders at the 5th HTA Stakeholder Meeting:
– Patients must be co-creators, not bystanders;
– Training is key–patient experts need the right tools;
– Metrics matter–patients should have a voice in what’s measured.”
At the 5th Health Technology Assessment-HTA Stakeholder Meeting, EHC made one thing clear: patients are not passive participants—they are partners in progress.
Here is what the day reinforced:
- HTA can’t afford to be a closed-door process. People living with bleeding disorders must be involved from the start—not as an afterthought, but as co-authors of the system that evaluates their care.
- What gets measured gets valued. Patients deserve a voice in defining what outcomes truly matter, beyond charts and cost curves.
Overall, this meeting was a reminder that HTA isn’t just about cost-effectiveness. It’s about people.
More on the news of bleeding disorders in Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia